The study reported an overall response rate of 26% in 19 patients with cervical cancer [32], while another phase IB study using anti-PD‐1 in 24 women with PD-L1-positive cervical cancer reported a 17% overall response rate [33]. The gene discussed is CD274; the disease is cervical carcinoma.